SCHEMBL21392777

SCHEMBL21392777

O=C(c1ccccc1)N1CCC(c2nc3ccccc3s2)CC1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 13/20 0.82
DCUN1D1 Q96GG9 13/20 0.82
LMNA P02545 4/20 0.82
TP53 P04637 4/20 0.82
MAPT P10636 4/20 0.77
ALDH1A1 P00352 2/20 0.77
MEN1 O00255 1/20 0.77
CYP1A2 P05177 1/20 0.77
CYP3A4 P08684 1/20 0.77
CYP2C9 P11712 1/20 0.77
CYP2C19 P33261 1/20 0.77
RECQL P46063 1/20 0.77
KMT2A Q03164 1/20 0.77
GAA P10253 1/20 0.77
GFER P55789 1/20 0.77
TSHR P16473 2/20 0.71
POLB P06746 1/20 0.71
MAPK1 P28482 1/20 0.71
HTT P42858 1/20 0.71
NPSR1 Q6W5P4 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18657424 0.90 UBE2M (1.00) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL18657962 0.90 UBE2M (0.79) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL18657535 0.90 UBE2M (1.00) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL18657542 0.90 UBE2M (0.79) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL21392790 0.88 UBE2M (0.76) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL18657973 0.87 UBE2M (1.00) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL18657539 0.87 UBE2M (1.00) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL18657538 0.87 UBE2M (1.00) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL18657544 0.85 UBE2M (0.78) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL18657534 0.85 UBE2M (1.00) UBE2MDCUN1D1LMNATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 UBE2M 762/4885DCUN1D1 2998/4885LMNA 1016/4885
US-11666661-B2 Methods and compounds for targeted autophagy ATG7, BECN1, SQSTM1 UBE2M 762/4885DCUN1D1 2998/4885LMNA 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.